Aeterna Zentaris (AEZS), Armune BioScience Finalize APIFINY Agreement
- Wall Street ekes out gains to close languid week
- 'Faster than Porsche but Safer than Volvo': Tesla (TSLA) Begins Model S Plaid Deliveries, Priced Between $131,100 and $145,600
- Oil hits multi-year highs in third weekly gain on demand recovery
- Snowflake (SNOW) Falls Following Investor Day Despite Strong Guidance, Analysts Bullish But Say Investors May Have Wanted More
- Dollar looks stronger as euro and sterling dip
Aeterna Zentaris (NASDAQ: AEZS) announced the finalization of a co-marketing agreement with Armune BioScience, Inc. (“Armune”) that will allow the Company to promote Armune’s APIFINY, the only cancer specific, non-PSA blood test for the detection of prostate cancer.
Under the co-marketing agreement, the Company will promote APIFINY to designated medical professionals in its U.S. territories and will receive a commission for each test performed resulting from its targeted promotion. Jude Dinges, Senior Vice President and Chief Commercial Officer of Aeterna Zentaris, commented on the agreement: “APIFINY represents an important addition to clinical information pertaining to the detection of prostate cancer. It is a simple, non-PSA based measure for patients and their clinicians to aid in assessment of prostate cancer risk. Importantly, this product enhances our focus on the oncology marketplace in general and on the diagnosis, monitoring and treatment of prostate cancer in particular. It was recently reported that our Zoptrex™ product has demonstrated potential as a treatment for certain types of prostate cancer in an investigator-sponsored Phase II trial and, therefore, we have a keen interest in products that relate to the condition.”
Discussing the potential for a broader collaboration between the Company and Armune, Richard Sachse, MD PhD, Senior Vice President and Chief Scientific Officer of the Company, commented, “It will be an exciting opportunity to qualify APIFINY as a companion diagnostic for therapeutic decision-making and for disease-monitoring within our ongoing Zoptrex™ development program or potential successor programs, if we decide to go forward in prostate cancer or any other cancer suitable for Armune’s compelling technology platform.”
David A. Dodd, Chairman, President and Chief Executive Officer of the Company, commented on the opportunity, stating “Promoting APIFINY will give our sales force experience in the oncology market, which will serve us well as we move toward the commercialization of Zoptrex™, if it is approved by the FDA. We are also looking forward to developing a much more in-depth relationship with Armune in connection with the evaluation of Zoptrex™ for prostate cancer and perhaps other indications.”
“We are very excited to begin our partnership with Aeterna Zentaris through this initial agreement,” commented David A. Esposito, President and Chief Executive Officer of Armune BioScience. “The experience and expertise of the commercial and research teams at Aeterna Zentaris will be extremely helpful to Armune as we accelerate the growth of APIFINY and develop our autoantibody technology across major areas of unmet need in cancer. In less than eight months on the market, APIFINY has been ordered over 2,500 times as clinicians move beyond PSA-based testing to assess prostate cancer risk. Aeterna Zentaris will help us achieve the full potential of this opportunity.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apollo Global Management (APO) Expands Board to 18-Members; Adds David Simon, Jim Belardi, Mitra Hormozi, Marc Beilinson and Lynn Swann to Board
- Recon Technology (RCON) Updates Progress on its Technology-Driven Solutions for Electric Submersible Progressing Cavity Pump with $5 Million Orders Secured
- MediaCo (MDIA) announces Rahsan-Rahsan Lindsay has been named Chief Executive Officer
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!